This HTML5 document contains 35 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB08941/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08941
rdf:type
n3:Drug
n3:description
A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.
n3:group
withdrawn approved
owl:sameAs
n6:DB08941
dcterms:title
Isoxsuprine
adms:identifier
n9:DB08941
n3:IUPAC-Name
n4:271B5E81-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5E87-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5E86-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5E83-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5E84-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5E85-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5E7F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5E80-363D-11E5-9242-09173F13E4C5 n4:271B5E7D-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5E7E-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:C04AA01
n3:H-Bond-Acceptor-Count
n4:271B5E8D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5E8E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5E88-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5E89-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5E8B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5E8A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5E8C-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
395-28-8
n3:Bioavailability
n4:271B5E93-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5E95-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5E96-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5E92-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5E91-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5E94-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5E82-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5E8F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5E90-363D-11E5-9242-09173F13E4C5